Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER120
- Development stage
- Phase 3
- Lead developer
- Serodus
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
SER120 is a very low-dose desmopressin nasal spray formulation developed for the treatment of nocturia (waking at night to void). It works by reducing urine production during sleep. In Phase 3 clinical trials, SER120 demonstrated significant efficacy in reducing nocturic episodes in patients with various underlying etiologies including nocturnal polyuria, overactive bladder, and benign prostatic hyperplasia.
- Brand names
- Noctiva
- Other names
- desmopressin acetate nasal spraydesmopressin nasalDDAVP nasalDDAVP Rhinal Tube nasalStimate nasal
02
Targets
AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on SER120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER120.